Z

Zosano Pharma Corp
F:0ZPN

Watchlist Manager
Zosano Pharma Corp
F:0ZPN
Watchlist
Price: 0.525 EUR Market Closed
Market Cap: €18.9m

Zosano Pharma Corp
Accounts Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Zosano Pharma Corp
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zosano Pharma Corp
F:0ZPN
Accounts Receivables
$110k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Accounts Receivables
$2.9B
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
9%
Edwards Lifesciences Corp
NYSE:EW
Accounts Receivables
$659.6m
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
8%
Stryker Corp
NYSE:SYK
Accounts Receivables
$4B
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Accounts Receivables
$7.9B
CAGR 3-Years
10%
CAGR 5-Years
5%
CAGR 10-Years
9%
Intuitive Surgical Inc
NASDAQ:ISRG
Accounts Receivables
$1.5B
CAGR 3-Years
17%
CAGR 5-Years
19%
CAGR 10-Years
15%
No Stocks Found

Zosano Pharma Corp
Glance View

Market Cap
18.9m EUR
Industry
Health Care

Zosano Pharma Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Fremont, California and currently employs 40 full-time employees. The company went IPO on 2015-01-27. Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The firm is focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using its transdermal microneedle system (the System). Its System is designed to facilitate rapid drug absorption into the bloodstream, and to provide an improved pharmacokinetic (PK) profile compared to original dosage forms. The System consists of a three cm square to six cm square array of titanium microneedles approximately 200-350 microns in length, coated with a hydrophilic formulation of drug, mounted on an adhesive patch. The company is focused on development of its lead product candidate, M207, a formulation of zolmitriptan, which is used as an acute treatment for migraine. Its zolmitriptan formulation is delivered utilizing its system. M207 is designed to provide rapid absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract.

0ZPN Intrinsic Value
Not Available
Z

See Also

What is Zosano Pharma Corp's Accounts Receivables?
Accounts Receivables
110k USD

Based on the financial report for Mar 31, 2022, Zosano Pharma Corp's Accounts Receivables amounts to 110k USD.

What is Zosano Pharma Corp's Accounts Receivables growth rate?
Accounts Receivables CAGR 1Y
-54%

Over the last year, the Accounts Receivables growth was -54%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett